Context: Primary resistance occurs when a person becomes infected with a resistant strain of TB. A person with fully susceptible MTB may develop secondary (acquired) resistance during therapy because of inadequate treatment, not taking the prescribed regimen appropriately (lack of compliance), or using low-quality medication. Drug-resistant TB is a serious public health issue in many developing countries, as its treatment is longer and requires more expensive drugs. MDR-TB is defined as resistance to the two most effective first-line TB drugs: rifampicin and isoniazid. Extensively drug-resistant TB is also resistant to three or more of the six classes of second-line drugs. Totally drug-resistant TB is resistant to all currently used drugs. It was first observed in 2003 in Italy, but not widely reported until 2012, and has also been found in Iran and India. Bedaquiline is tentatively supported for use in multiple drug-resistant TB.

Question: If a person has TB that's resistant to rifampicin and isoniazid, which type of the disease do they have?
Answer: MDR-TB

Question: What's the minimum number of second-line medication classes your TB would have to resist to make it count as "extensively drug-resistant"?
Answer: three

Question: In what country was the first case of totally drug-resistant tuberculosis?
Answer: Italy

Question: What's the only antibiotic that might be effective against totally drug-resistant TB?
Answer: Bedaquiline

Question: Cases of totally drug-resistant TB have been found in what country in addition to Italy and India?
Answer: Iran

Question: Someone who is not susceptible to MTP develops what?
Answer: Unanswerable

Question: What is low-quality medication an example of a lack of?
Answer: Unanswerable

Question: What was first reported in Iran?
Answer: Unanswerable

Question: When was MDR-TB first observed?
Answer: Unanswerable

Question: Where was bedaquiline created?
Answer: Unanswerable